Find therapies in clinical trials near you – page 485

Safety, Tolerability and Pharmacokinetics of Zosurabalpin After Multiple Intravenous Doses in Healthy Participants

Study on Ritlecitinib for Adults and Adolescents with Nonsegmental Vitiligo

Study on Ritlecitinib for Adults and Adolescents with Nonsegmental Vitiligo

Phase 3 Study of Zigakibart (BION-1301) in Adults with IgA Nephropathy

Oral Tramadol Hydrochloride Study in Healthy Volunteers to Improve Detection in Anti‑Doping Tests

Oral Tramadol Hydrochloride Study in Healthy Volunteers to Improve Detection in Anti‑Doping Tests

Safety, Tolerability and Pharmacokinetics of Oral PF-07293893 in Healthy Adults for Future Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Safety, Tolerability and Pharmacokinetics of Oral PF-07293893 in Healthy Adults for Future Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Pharmacokinetic Modeling of Oral and Intranasal Zolmitriptan in Healthy Volunteers

Fed‑State Bioequivalence Study of Nitrofurantoin 100 mg Prolonged‑Release Capsules in Healthy Volunteers

Relative Bioavailability of Sisunatovir Capsules vs Tablets in Fasted and Fed Conditions in Healthy Adults with Respiratory Syncytial Virus

Relative Bioavailability of Sisunatovir Capsules vs Tablets in Fasted and Fed Conditions in Healthy Adults with Respiratory Syncytial Virus

Pharmacokinetic Study of Ritlecitinib Tosilate in Healthy Adults: Oral Solution, Short‑and Long‑Duration Capsules Fed vs Fasted – for ulcerative colitis

Pharmacokinetic Study of Ritlecitinib Tosilate in Healthy Adults: Oral Solution, Short‑and Long‑Duration Capsules Fed vs Fasted – for ulcerative colitis

Effect of gut microbiome on tacrolimus pharmacokinetics with drug combination in healthy volunteers

Study of alogabat oral 60 mg capsule and IV 100 µg microdose in healthy male participants to assess mass balance, absolute bioavailability and metabolism

Safety and Immunogenicity of SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER Vaccine in Adults with COVID-19

Safety and Immunogenicity of SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER Vaccine in Adults with COVID-19